Commercialization
Tag
Apr 02, 2024

FDA approves first cell therapy in landmark achievement for personalized medicine
Mar 25, 2024

OICR-supported cancer therapeutics company Fusion Pharmaceuticals acquired by AstraZeneca for up to US $2.4 billion
Aug 08, 2022

FACIT pitch competition empowers Ontario’s oncology entrepreneurs
Apr 28, 2022

Two OICR innovations bolstered by investments from FACIT
Feb 10, 2022

FACIT award winners to give surgeons 10-second solution to identify cancer
Jun 18, 2019

From idea to impact: An expanding solution to a common surgical problem
Feb 07, 2019

Op-ed in The Globe and Mail hails innovation strategy that resulted in record-breaking investment by Celgene
Jan 29, 2019

New potential treatment for leukemia discovered by OICR scientists draws major industry investment
Aug 02, 2018

Ontario centre attracts national attention for probe research, development and commercialization
Jun 27, 2018

Healthcare Software Start-Up Ziliomics Financed by FACIT
Apr 12, 2018

Restorative Breast Cancer Solution Start-Up Wins the 2018 FACIT Pitch Competition
Oct 04, 2017

FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A
Aug 09, 2017

CIMTEC appoints Justin Leushner as new CEO
Aug 01, 2017

FACIT launches cross-border campaign to recruit clinical scientists and biotechnology industry executives
Mar 22, 2017

FACIT Launches The Prospects Oncology Fund
Jul 04, 2016

FACIT Falcons’ Fortunes pitch competition helps Ontario ideas take flight
Mar 16, 2016

FACIT invests in new CPDC spin-out company to aid development of potent radiotherapeutic
Jan 07, 2015

Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers
Looking Ahead
Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.